Objective To explore the application of low-molecular-weightheparin (LMWH) in the procedure of coronary stent implantation.
目的探讨低分子肝素(LMWH)在冠状动脉支架术中的应用价值及安全性。
2
The patient was diagnosed with DVT of the left leg, and low-molecular-weightheparin (nadroparin 0·4 mL, two times per day) was started, lasting 2 weeks.
病人诊断为左下肢DVT，并使用低分子肝素（那曲肝素0·4 mL，一日两次）持续治疗两周。
3
When compared with each other, low-molecular-weightheparin was associated with a 32 percent reduced risk of deep vein thrombosis and a 53 percent lower rate of hematoma at the injection site.